← Back to Search

T2* Imaging for Sarcoma

N/A

Recruiting

Led By Bryan Allen, MD, PhD

Research Sponsored by Bryan Allen

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG 0, 1, or 2

Pathologically confirmed Sarcoma, by biopsy or excision

Must not have

Age less than 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 8 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing if radiation therapy can change the amount of iron in a sarcoma tumor.

Who is the study for?

This trial is for adults with pathologically confirmed Sarcoma who are prescribed radiation therapy. They should be able to perform daily activities (ECOG 0, 1, or 2) and must consent to participate. Treatment should start within five weeks after surgery or biopsy.

What is being tested?

The study is testing T2* MRI imaging on sarcoma tumors to see if radiation therapy affects the iron levels in these tumors. It's a small pilot study designed to explore this potential relationship.

What are the potential side effects?

Since the intervention being studied is an imaging technique and not a drug, there are no direct side effects from T2* MRI itself; however, standard risks associated with MRIs apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and perform daily activities.

Select...

My sarcoma diagnosis was confirmed through a biopsy or surgery.

Select...

I am receiving radiation therapy as recommended by my doctor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in ferric iron levels detected by T2* MRI

Secondary study objectives

Change in ferrous iron levels detected by T2* MRI

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: T2* ImagingExperimental Treatment1 Intervention

Participants undergo T2\* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.

0 / 4Eligibility criteria met